N.B. The English language version of these minutes is an unofficial translation. In case of any discrepancy between the English and German language versions, the German language version shall prevail.

Minutes from the annual general meeting of Implantica AG (publ), reg. no. FL-0002.629.889-3, held on May 10, 2022, at 11:00 (CET) at Implantica AG, Äulestrasse 45, 9490 Vaduz, Liechtenstein

For the agenda item, the Chairman submits the following:

- 1. Welcome and statements
- 2. Resolution and adoption of the statutory financial statements and the consolidated financial statements of Implantica AG
- 3. Resolution on the net result in accordance with the adopted balance sheet
- 4. Resolution on discharge of the Board of Directors, Executive Management, and the Auditors
- 5. Election of the Board of Directors and the Chairman and Vice-Chairman of the Board of Directors
- 6. Election of members and Chairman of the Nomination and Remuneration Committee
- 7. Election of the independent proxy
- 8. Election of the auditors
- 9. Resolution on approval of remuneration of the Board of Directors and Executive Management
- 10. Resolution on the Long-term Incentive Plan no new shares authorized
- 11. Resolution on the authorization of acquisition of treasury shares upon board resolution

The agenda was unanimously approved.

### Regarding agenda item 1:

I. Welcome and statements:

The Chairman welcomed those present and noted:

- Andreas Öhrnberg, as Chairman, opened the Ordinary General Meeting at 11:00;
- the Chairman noted that, due to the special measures applicable under Covid-19, the Ordinary General Meeting is held without the physical presence of shareholders and that all shareholders had the opportunity to exercise their voting rights by proxy and to submit questions and comments in advance by e-mail;
- the Chairman noted that today's General Meeting was duly convened in the manner provided for by the Articles of Association at least 20 days before the date of the meeting. The invitation, together with the agenda, was published in the Company's official publication at www.implantica.com;

- the Chairman stated that the invitation, notice and publication of the documents were thus duly issued and made available in due time.

No objections were raised to these findings.

### II Presence:

Before dealing with the agenda items, the Chairman gave the floor to the vote counter, who read out the presence as follows:

	Class A shares	Class B shares	Total
	(par value CHF	(par value CHF	
	2.00 / share)	0.02 / share)	
Votes represented	28'358'474	1'125'000'000	1'153'358'474
Thereof by shareholders	0	0	0
Of which by the independent	28'358'474	1'125'000'000	1'153'358'474
proxy			
Share capital represented in CHF	56'716'948.00	22'500'000.00	79'216'948.00

The Chairman noted that out of a total of 1,183,111,537 shares, 1,153,358,474 shares were present or represented.

The Chairman noted that at this Ordinary General Meeting of Shareholders there was no physical presence of the shareholders and therefore all votes were represented by the independent proxy.

The Chairman also noted that the participation of the external auditors KPMG (Liechtenstein) AG, Vaduz, had been waived.

No objections were raised to these findings.

# Regarding agenda item 2:

The Board of Directors proposed the approval of the Annual Report 2021, consisting of the statutory financial statements and the consolidated financial statements of Implantica AG, acknowledging the reports of the auditors.

The Annual General Meeting unanimously approved the proposal of the Board of Directors.

# Regarding agenda item 3:

The Board of Directors proposed to carry forward the net loss for the financial year 2021 and not to distribute a dividend.

The Annual General Meeting unanimously approved the proposal of the Board of Directors.

### Regarding agenda item 4:

The Board of Directors proposed that the Annual General Meeting discharge the members of the Board of Directors, the Executive Committee and the auditors from liability for their activities in the financial year 2021.

The Annual General Meeting unanimously approved the proposal of the Board of Directors.

### Regarding agenda item 5:

The Board of Directors proposed to the Annual General Meeting:

- Re-election of Liselott Kilaas as member and Chairman of the Board of Directors for a term of office until completion of the next Annual General Meeting of Shareholders;
- Re-election of Johan Bojs as member and Vice Chairman of the Board of Directors for a term of office until the conclusion of the next Annual General Meeting of Shareholders;
- Re-election of Thomas Puusepp, Klaus Neftel and Stephan Siegenthaler as members of the Board of Directors in separate elections for a term of office until the conclusion of the next Annual General Meeting.

The Annual General Meeting unanimously approved the proposals of the Board of Directors.

### Regarding agenda item 6:

The Board of Directors proposed the re-election of Johan Bojs as Chairman and Klaus Neftel as member of the Nomination and Remuneration Committee for a term of office until completion of the next Annual General Meeting.

The Annual General Meeting unanimously approved the proposal of the Board of Directors.

## Regarding agenda item 7:

The Board of Directors proposed the re-election of Philipp Wanger, Attorney at Law, Neugasse 17, 9490 Vaduz, as independent proxy until the next Annual General Meeting.

The General Meeting unanimously approved the proposal of the Board of Directors.

### Regarding agenda item 8:

The Board of Directors proposed the re-election of KPMG (Liechtenstein) AG, Aeulestrasse 2, 9490 Vaduz, as auditors for the financial year 2022.

The General Meeting unanimously approved the proposal of the Board of Directors.

### Regarding agenda item 9:

The Board of Directors proposed that the Annual General Meeting

- approves the total compensation of the Board of Directors of EUR 179 thousand and
  of the Executive Board of EUR 766 thousand for the financial year 2021. The total
  remuneration includes the fixed compensation, the pension contributions, and the
  long-term share-based incentive plan.
- The Executive Committee comprises the Chief Executive Officer, the Chief Strategy
   Officer, the Chief Financial Officer, and the VP Operations & IR.

The Annual General Meeting approved the proposal of the Board of Directors regarding the Board of Directors with 1,149,118,474 votes in favor, 4,220,000 against and 0 abstentions.

The General Meeting unanimously approved the proposal of the Board of Directors with regards to the Executive Board.

### Regarding agenda item 10:

The Board of Directors proposed that it shall be authorized to execute the "Long-Term Incentive Plan", a 5-year stock option plan for Class A shares in 5 equal tranches, under which senior executives and selected key employees will be rewarded with share-based incentives, such as, but not limited to, options, restricted stock units and contingent share awards, as determined by the Board of Directors, but not exceeding 5% of the outstanding Class A shares of Implantica AG, valid until May 2027.

The Annual General Meeting approved the proposal of the Board of Directors with 1,149,118,474 votes in favor, 4,220,000 against and 0 abstentions.

### Regarding agenda item 11:

The Board of Directors proposed that Implantica AG shall be authorized until May 10, 2027, upon according resolutions of the Board of Directors, to acquire treasury shares of up to 10% of the fully paid registered shares with a nominal value of CHF 2.00 (Class A shares) outstanding at the time of the adoption of the resolution by the General Meeting through the acquisition of Swedish Depository Receipts (SDR).

The acquisition of treasury shares may be exercised in whole or in part, once or several times, by the Board of Directors.

The Annual General Meeting approved the proposal of the Board of Directors with 1,150,856,783 votes in favor, 2,501,691 against and 0 abstentions.

After all items on the agenda have been dealt with and there were no further questions, the Chairman closed the Annual General Meeting at 11:40 a.m.

Vaduz, 10. May 2022

Andreas Öhrnberg (Chairman)

Philipp Wanger (Secretary)



# Notice of Annual General Meeting of Implantica AG

The shareholders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby given notice of the annual general meeting on Tuesday, May 10, 2022, at 11:00.

Pursuant to Act 5 from November 2021 in the context of Covid-19 (COVID-19-VJBG), accompanying measures in judicial and administrative procedures continue to be in force. Therefore, the annual general meeting on Tuesday, May 10, 2022, will be held without the physical presence of participants and personal participation of shareholders and only the statutorily required people will attend the meeting. The meeting process will include control that the meeting was duly convened and control of the shareholder and voting lists.

Depository receipt holders will be able to vote by submitting their voting form to Pareto Securities AB (the "Custodian"), who will forward the votes to the independent proxy (Article 11 para. 4 lit. b of the Act of 8 April 2020 on accompanying measures in judicial and administrative procedures in the context of Covid-19, LGBI 2020/136).

Depository receipt holders have the opportunity to submit questions in respect of the AGM by sending them to <a href="mailto:investorrelations@implantica.com">investorrelations@implantica.com</a> before May 10, 2022.

### Right to participate

Those wishing to participate in the meeting, through postal voting, must

- Be entered as depository receipt holders in the Swedish Depository Receipt ("SDR") register kept by the Swedish central securities depository Euroclear Sweden on Wednesday, April 27, 2022 and
- Cast their vote no later than Monday, May 2, 2022, in accordance with the instructions on the Postal Voting Form, see appendix 1, so that the voting form is received by Pareto Securities AB no later than that day.

Holders of depository receipts who hold their receipts through nominees (Sw. förvaltare) must request a temporary registration of the voting rights in order to be able to participate at the Meeting. Holders of depository receipts who want to obtain such registration must contact the nominee regarding this in advance of April 27, 2022.

### Proposed agenda

- 1. Resolution and adoption of the statutory financial statements and the consolidated financial statements of Implantica AG
- 2. Resolution on the net result in accordance with the adopted balance sheet
- 3. Resolution on discharge of the Board of Directors, Executive Management and the Auditors
- **4.** Election of the Board of Directors and the Chairman and Vice-Chairman of the Board of Directors
- 5. Election of members and Chairman of the Nomination and Remuneration Committee
- **6.** Election of the independent proxy
- 7. Election of the auditors
- **8.** Resolution on approval of remuneration of the Board of Directors and Executive Management
- 9. Resolution on the Long-term Incentive Plan no new shares Authorized
- 10. Resolution on the authorization of acquisition of treasury shares upon board resolution

### Agenda items

The following agenda items are scheduled for the Annual General Meeting ("AGM"):

## Resolution and adoption of the statutory financial statements and the consolidated financial statements of Implantica AG

Proposal of the Board of Directors:

Approval of the annual report 2021 consisting of the statutory financial statements and the consolidated financial statements of Implantica AG, acknowledging the reports of the auditors.

### 2. Resolution on the net result in accordance with the adopted balance sheet

Proposal of the Board of Directors:

Carry forward of the net loss for the financial year 2021 and to no payment of dividend.

# 3. Resolution on discharge of the Board of Directors, Executive Management and the Auditors

Proposal of the Board of Directors:

- a) Granting of discharge to the members of the Board of Directors for financial year 2021.
- b) Granting of discharge to the members of the Executive Management for financial year 2021.
- c) Granting of discharge to the Auditor for financial year 2021.

# 4. Election of the Board of Directors and the Chairman and Vice-Chairman of the Board of Directors

The Board of Directors of the company currently consists of five ordinary members. It is proposed to re-elect all current board members for the period until the end of the next annual general meeting including the re-election of Liselott Kilaas as Chairman and Johan Bojs as Vice-Chairman.

Proposal of the Board of Directors:

- a) Re-election of Liselott Kilaas as member and Chairman of the Board of Directors for a term of office until completion of the next Annual General Meeting of shareholders.
- b) Re-election of Johan Bojs as member and Vice-Chairman of the Board of Directors for a term of office until completion of the next Annual General Meeting of shareholders.
- c) Re-election of Tomas Puusepp as member of the Board of Directors for a term of office until completion of the next Annual General Meeting of shareholders.
- d) Re-election of Klaus Neftel as member of the Board of Directors for a term of office until completion of the next Annual General Meeting of shareholders.
- e) Re-election of Stephan Siegenthaler as member of the Board of Directors for a term of office until completion of the next Annual General Meeting of shareholders.

#### 5. Election of members and Chairman of the Nomination and Remuneration Committee

Proposal of the Board of Directors:

Re-election of Johan Bojs as Chairman and Klaus Neftel as member of the Nomination and Remuneration Committee for a term of office until completion of the next Annual General Meeting of shareholders.

# 6. Election of the independent proxy

Proposal of the Board of Directors:

Re-election of Philipp Wanger, Attorney-at-law, Neugasse 17, 9490 Vaduz, Liechtenstein as independent proxy until the next annual general meeting of shareholders.

#### 7. Election of the auditors

Proposal of the Board of Directors:

Re-election of KPMG (Liechtenstein) AG, Aeulestrasse 2, 9490 Vaduz, Liechtenstein as auditor for the financial year 2022.

# 8. Resolution on approval of remuneration of the Board of Directors and Executive Management

Proposal of the Board of Directors:

- a) Approve the total remuneration of the Board of Directors of EUR 179 thousand for financial year 2021. The total remuneration includes fixed compensation, pension contributions and long-term share-based incentive plan.
- b) Approve the total remuneration of the Executive Management of EUR 766 thousand for financial year 2021. The total remuneration includes fixed compensation, pension contributions and long-term share-based incentive plan. Executive Management is made up of the Chief Executive Officer, the Chief Strategy Officer, the Chief Financial Officer and the VP Operations & IR.

### 9. Resolution on the Long-term Incentive Plan - No new shares Authorized

Proposal of the Board of Directors (Consultative Vote):

The board of directors shall continue to be authorized to execute the Long-Term Incentive Plan, a 5-year stock option plan of Class A shares in 5 equal installments, under which senior executives and selected key employees will be rewarded with share-based incentives such as, but not limited to, options, restricted stock units and contingent share awards as to be specified by the board of directors, however, not exceeding 5% of the outstanding Class A-shares of Implantica AG valid until May 2027.

### **Explanation:**

Implantica AG has continued to grant certain share-based rewards to senior executives and selected key employees and would like an iterative clarification approval by the AGM for our 5-year option plan of Class A-shares. The purpose of the Long-Term Incentive Plan is to attract, motivate and retain world class talent, whereas the design of the program shall be oriented towards long term incentives and alignment of interest with shareholders. Settlement of the rewards under the Incentive Plan may take place (i) via treasury shares that have been purchased in the open market, (ii) the utilization of contingent capital as per Article 4.4 of the Articles of Association or (iii) the issuance of existing authorized capital as per Article 4a.4.h of the Articles of Association.

### 10. Resolution on the authorization of acquisition of treasury shares upon board resolution

Proposal of the Board of Directors (Consultative Vote):

Implantica AG shall be authorized to acquire own shares, upon according resolutions of the board of directors, to the extent of up to 10% of the fully paid-up registered shares with a nominal value of CHF 2.00 (Class A Shares) outstanding at the time of the adoption of the resolution by the general meeting, through the acquisition of SDRs, until 10 May 2027. The acquisition of treasury shares may be exercised in whole or in part, once or several times, by the board of directors.

### Explanation:

The acquisition of SDRs shall be executed over the stock exchange at the market price without defined purpose. They may also be used to settle obligations towards senior executives and selected key employees of the group who shall be rewarded with shares in Implantica AG as part of their compensation package.

The acquisition of shares through SDRs, including shares which the company has previously acquired

and still holds, and shares which a third party has previously acquired and still holds in its own name but for the account of the Company, may not result in net assets, falling below the amount of subscribed capital plus reserves whose distribution is not permitted by law or the articles of association.

For purpose of clarity, the Company is authorized to exclude the statutory subscription rights of the shareholders pursuant to Art. 303 et seq. PGR upon the disposal of the treasury shares until 10 May 2027.

## **Voting**

Depository receipt holders are invited to send their votes to the Custodian as outlined in the Postal Voting Form (appendix 1). The Custodian will forward the votes for representation to the local independent proxy, Mr. Philipp Wanger, Attorney-at-law.

### **Minutes**

The minutes of the annual general meeting will be available for review from the evening of May 27, 2022, at the latest at the company's headquarters, Aeulestrasse 45, 9490 Vaduz, Liechtenstein and on the company's website <a href="https://www.implantica.com">www.implantica.com</a>.

## **Implantica AG**

The Board of Directors April 20, 2022



# Notification of participation and form for postal voting

by postal voting in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations.

The form must be received by Pareto Securities AB (who are administering the postal voting forms on behalf of Implantica AG) no later than May 2, 2022.

The SDR holder set out below hereby notifies the company of its participation and exercises its voting right for all of the SDR holder's SDRs in Implantica AG, Reg No FL-0002.629.889-3, at the General Meeting on May 10, 2022. The voting right is exercised in accordance with the voting options marked below.

SDR holder name	Personal ID no. / Company registration no	

Assurance (if the undersigned is a legal representative of a shareholder who is a <u>legal entity</u>): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this postal vote on behalf of the shareholder and that the contents of the postal vote correspond to the shareholder's decisions

Assurance (if the undersigned represents the shareholder <u>by proxy</u>): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

Place and date		
Signature (proxies and legal representatives should use their own signature)		
Clarification of signature (proxies and legal representatives should use their own name)		
Telephone no.	E-mail	



#### **Instructions:**

- Complete the information above
- Select the preferred voting options below
- Print, sign and send the form to Implantica AG, c/o Pareto Securities AB, Box 7415, 103 91
  Stockholm, Sweden. Label the envelope "AGM 2022". A completed and signed form may
  also be submitted electronically and shall, in such case, be sent by e-mail to
  issueservice.se@paretosec.com.
- If the SDR holder is a natural person who is personally voting by post, it is the SDR holder who should sign under *Signature* above. If the postal vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the postal vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- If the shareholder votes by proxy, a power of attorney should be appended to the postal voting form. In case the SDR holder is a legal entity, documentation evidencing that the person signing the application form is authorized to do so must accompany the application form.
- Please note that shareholders with nominee registered shares must register the shares in their own name to be entitled to vote. Instructions in this regard can be found in the notice to the general meeting.

The SDR holder cannot include any other instructions than selecting one of the options specified at each item in the form. If a SDR holder wishes to abstain from voting in relation to an item, kindly refrain from selecting an option. If the shareholder has included any special instructions or conditions in the form or made changes to preprinted texts, the vote is invalid in its entirety. Only one voting form per SDR holder will be considered. If more than one form is submitted, the form with latest date will be considered. The last received form will be considered if more than one form is submitted with the same date. Incomplete or incorrectly completed forms may be discarded.

The voting form, together with any appended authorization documents, shall be received by Pareto Securities AB by May 2, 2022, at the latest. A submitted vote can be withdrawn up to and including May 2, 2022 in the same manner as the mail vote was submitted.



# General Meeting in Implantica AG May 10, 2022

Below, the SDR holder can state how it wishes to vote in the matters included in the proposed agenda, which is set out in the notice of the General Meeting. "Yes" means that the shareholder votes in accordance with the proposal that is set out in the notice to the general meeting and "No" means that the shareholder votes against the proposal that is set out in the notice to the general meeting.

Please refer to the notice for the General Meeting on Implantica AG's website, <u>www.implantica.com</u>, for complete proposals.

1. Resolution and adoption of the statutory financial statements and the consolidated financial			
statements of Implantica AG			
Yes □ No □			
2. Resolution on the net result in accordance with the adopted balance sheet			
Yes □ No □			
3. Resolution on discharge of the Board of Directors, Executive Management and the Auditors			
3.1 Board of Directors			
Yes □ No □			
3.2 Executive Management			
Yes □ No □			
3.3 Auditors			
Yes □ No □			
4. Election of the Board of Directors and Chairman and Vice-Chairman of the Board of Directors			
4.1 Liselott Kilaas (re-election)			
Yes □ No □			
4.2 Johan Bojs (re-election)			
Yes □ No □			
4.3 Tomas Puusepp (re-election)			
Yes □ No □			
4.4 Klaus Neftel (re-election)			
Yes □ No □			
4.5 Stephan Siegenthaler (re-election)			
Yes □ No □			
4.6 Election of Liselott Kilaas as the Chairman of the Board (re-election)			
Yes □ No □			
4.7 Election of Johan Bojs as the Vice-Chairman of the Board (re-election)			
Yes □ No □			
5. Election of members and Chairman of the Nomination and Remuneration Committee			
5.1 Johan Bojs (re-election)			
Yes □ No □			
5.2 Klaus Neftel (re-election)			
Yes □ No □			
5.3 Election of Johan Bojs as Chairman of the Nomination and Remuneration Committee (re-			
election)			
Yes □ No □			
6. Election of the independent proxy			
Philipp Wanger, Attorney-at-law, 9490 Vaduz, Liechtenstein (re-election)			
Yes □ No □			
7. Election of the auditors			



KPMG (Liechtenste	ein) AG (re-election)				
Yes □	No □				
8. Resolution on approval of remuneration of the Board of Directors and Executive					
Management					
8.1 Board of Direct	ors				
Yes □	No □				
8.2 Executive Mana	8.2 Executive Management				
Yes □	No □				
9. Resolution on th	ne Long-term Incentive Plan – No new shares Authorized				
Yes □	No □				
10. Resolution on the authorization of acquisition of treasury shares upon board resolution					
Yes □	No □				
A shareholder that wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting can state this below (should only be used if the shareholder has such a request). Please use numerals.					
Item(s):					